talquetamab,teclistamab
genmab,janssen
['multiple myeloma', 'talquetamab', 'tecvayli', 'janssen']
janssen reports 96% response rate in phase 1b study of tecvayli and talquetamab for multiple myeloma patients. #jnj #asco2023 #positive 
Real-time news analysis & sentiment scoring (+/-) for stocks
Powered by @streetbeat_com
From the creators of @uscongbuysnews
Disclosure: https://t.co/eNe8LEd7CU